This article was originally published in Start Up
Aiming to move pathology into the molecular age, HistoRx Inc. will use its tissue-analysis algorithms, termed AQUA, to automate quantitative analysis of proteins in tissue samples for drug discovery and development. Eventually, HistoRx wants to use its reagents and in situ diagnostic instrumentation and software to replace the clinical pathologist's eye for biomarker analysis.
You may also be interested in...
Analyzing the venture financings closed by 2004's new crop of biotech, diagnostics, and medical device start-ups reveals today's trends that may shape tomorrow's health care industry. Here we point out eleven 2004 Series A financings that identify and illustrate what's hot.
Marks appeared to use the variable EUA bar to justify what many viewed as early mistakes by FDA during COVID-19, and to emphasize the importance of physician awareness of the strength of evidence used to authorize a drug.